Veracyte, Inc.

NasdaqGM:VCYT

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

📊 Big Data

🧬 Biotechnology

🩺 Medical Instruments

💻 Telehealth

Location

United States

Market Cap

USD 2.09 B

Share Price

USD 26.71

Avg Daily Volume

1,025,626

Change (1 day)

1.21%

Change (1 year)

18.50%

Change (YTD)

-32.55%

Veracyte, Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2025: USD 463.39 M

Veracyte, Inc. Revenue is USD 463.39 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 23.42% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Veracyte, Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 375.47 M, a 20.66% change year over year.
Veracyte, Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 311.18 M, a 24.17% change year over year.
Veracyte, Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 250.59 M, a 103.63% change year over year.
Veracyte, Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 123.06 M, a 0.90% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

NasdaqGM: VCYT

Veracyte, Inc.

CEO	Mr. Marc A. Stapley
IPO Date	Oct. 30, 2013
Location	United States
Headquarters	6000 Shoreline Court
Employees	824
Sector	🏥 Health Care
Industries Clinical Trials 📊 Big Data 🧬 Biotechnology 🩺 Medical Instruments 💻 Telehealth

Description

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.